miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma

Ferroptosis is a regulated form of cell death driven by small molecules or conditions that induce lipid-based reactive oxygen species (ROS) accumulation. This form of iron-dependent cell death is morphologically and genetically distinct from apoptosis, necroptosis, and autophagy. miRNAs are known to...

Full description

Saved in:
Bibliographic Details
Published inCell death and differentiation Vol. 25; no. 8; pp. 1457 - 1472
Main Authors Luo, Meiying, Wu, Longfei, Zhang, Kexin, Wang, Hong, Zhang, Tian, Gutierrez, Lucas, O’Connell, Douglas, Zhang, Peng, Li, Yu, Gao, Tongtong, Ren, Wenyan, Yang, Yongfei
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.08.2018
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Ferroptosis is a regulated form of cell death driven by small molecules or conditions that induce lipid-based reactive oxygen species (ROS) accumulation. This form of iron-dependent cell death is morphologically and genetically distinct from apoptosis, necroptosis, and autophagy. miRNAs are known to play crucial roles in diverse fundamental biological processes. However, to date no study has reported miRNA-mediated regulation of ferroptosis. Here we show that miR-137 negatively regulates ferroptosis by directly targeting glutamine transporter SLC1A5 in melanoma cells. Ectopic expression of miR-137 suppressed SLC1A5, resulting in decreased glutamine uptake and malondialdehyde (MDA) accumulation. Meanwhile, antagomir-mediated inactivation of endogenous miR-137 increased the sensitivity of melanoma cells to erastin- and RSL3-induced ferroptosis. Importantly, knockdown of miR-137 increased the antitumor activity of erastin by enhancing ferroptosis both in vitro and in vivo. Collectively, these data indicate that miR-137 plays a novel and indispensable role in ferroptosis by inhibiting glutaminolysis and suggest a potential therapeutic approach for melanoma.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1350-9047
1476-5403
DOI:10.1038/s41418-017-0053-8